Cargando…
Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
AIM: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs wi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190279/ https://www.ncbi.nlm.nih.gov/pubmed/29911889 http://dx.doi.org/10.2217/fmb-2018-0119 |
_version_ | 1783363533445005312 |
---|---|
author | Bagshaw, Emma Enoch, David A Blackney, Michael Posthumus, Jan Kuessner, Daniel |
author_facet | Bagshaw, Emma Enoch, David A Blackney, Michael Posthumus, Jan Kuessner, Daniel |
author_sort | Bagshaw, Emma |
collection | PubMed |
description | AIM: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs with ISAV versus L-AMB followed by POSA. MATERIALS & METHODS: As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration & monitoring, and hospitalization costs were evaluated from the healthcare system perspective. RESULTS: Per-patient costs were UK£14,842 with ISAV versus UK£18,612 with L-AMB followed by POSA. Savings were driven by drug acquisition, and administration & monitoring costs. CONCLUSION: ISAV has the potential to reduce IMD treatment costs relative to L-AMB followed by POSA. |
format | Online Article Text |
id | pubmed-6190279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Future Medicine Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-61902792018-10-19 Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK Bagshaw, Emma Enoch, David A Blackney, Michael Posthumus, Jan Kuessner, Daniel Future Microbiol Research Article AIM: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs with ISAV versus L-AMB followed by POSA. MATERIALS & METHODS: As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration & monitoring, and hospitalization costs were evaluated from the healthcare system perspective. RESULTS: Per-patient costs were UK£14,842 with ISAV versus UK£18,612 with L-AMB followed by POSA. Savings were driven by drug acquisition, and administration & monitoring costs. CONCLUSION: ISAV has the potential to reduce IMD treatment costs relative to L-AMB followed by POSA. Future Medicine Ltd 2018-09 2018-06-18 /pmc/articles/PMC6190279/ /pubmed/29911889 http://dx.doi.org/10.2217/fmb-2018-0119 Text en © 2018 Basilea Pharmaceutica International Ltd, Basel This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Research Article Bagshaw, Emma Enoch, David A Blackney, Michael Posthumus, Jan Kuessner, Daniel Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK |
title | Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK |
title_full | Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK |
title_fullStr | Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK |
title_full_unstemmed | Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK |
title_short | Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK |
title_sort | economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin b in the uk |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190279/ https://www.ncbi.nlm.nih.gov/pubmed/29911889 http://dx.doi.org/10.2217/fmb-2018-0119 |
work_keys_str_mv | AT bagshawemma economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk AT enochdavida economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk AT blackneymichael economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk AT posthumusjan economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk AT kuessnerdaniel economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk |